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Abstract
The Rare Cancer Network (RCN) was
formed in the early 1990’s to create a global
network that could pool knowledge and
resources in the studies of rare malignancies
whose infrequency prevented both their study
with prospective clinical trials. To date, the
RCN has initiated 74 studies resulting in 46
peer reviewed publications. The First
International Symposium of the Rare Cancer
Network took place in Nice in March of 2014.
Status updates and proposals for new studies
were heard for fifteen topics. Ongoing studies
continue for cardiac sarcomas, thyroid can-
cers, glomus tumors, and adult medulloblas-
tomas. New proposals were presented at the
symposium for primary hepatic lymphoma,
solitary fibrous tumors, Rosai-Dorfman dis-
ease, tumors of the ampulla of Vater, salivary
gland tumors, anorectal melanoma, midline
nuclear protein in testes carcinoma, pul-
monary lymphoepithelioma-like carcinoma,
adenoid cystic carcinoma of the trachea,
osteosarcomas of the mandible, and extra-cra-
nial hemangiopericytoma. This manuscript
presents the abstracts of those proposals and
updates on ongoing studies, as well a brief
summary of the vision and future of the RCN.
Introduction 
The Rare Cancer Network (RCN) held the
First International Symposium of the Rare
Cancer Network in Nice, France on March 21-
22, 2014 (Figure 1). The congress reports of
that meeting are presented in two companion
papers in this issue of Rare Tumors. The first
paper reviewed the history of the RCN and
selected works published to date. This manu-
script will review ongoing investigations and
the future vision of the RCN membership for
rare cancer research. More information on
open and proposed studies can be found on the
Rare Cancer Network webpage at
www.rarecancer.net. A summary of published
studies through 2012 can be found in the med-
ical literature in a recent review paper in Rare
Tumors journal. 1
Future of the Rare CancerNetwork
The Rare Cancer was founded over twenty
years ago by Professors René-Olivier
Mirimanoff and Mahumut Ozsahin. Although
the network as completed 54 joint scientific
studies and published 44 peer reviewed manu-
scripts, it was not until March 21-22, 2014 in
Nice, France that the group held its first offici-
al group meeting. The founder, René-Olivier
Mirimanoff, MD confirmed his desire to stop
the chair of the RCN and proposed to restruc-
ture the website and the follow-up activities of
this informal group, who since its creation
worked through internet and email diffusion.
All of the members agreed to proceed to the
creation of the RCN Board of Directors. After
the vote, Mahmut Ozsahin, MD, PhD was elect-
ed as the new president of the RCN. Yazid
Belkacemi, MD, PhD and Juliette Thariat, MD,
PhD became the new secretaries of the group,
and the board members were as follows: René-
Olivier Mirimanoff, MD, Marco Krengli, MD,
Robert Miller, MD, Luciano Scandolaro, MD,
Salvador Villa, MD, and Enis Ozyar, MD. The
board decided to create an official RCN associ-
ation, continue to its scientific activities in
rare cancer management, and to hold their
next meeting in Istanbul in March 2015. With
further collaboration and growing members,
the Rare Cancer Network will improve upon
not only the variety of data available to physi-
cians on rare malignancies, but also poten-
tially outcomes for patients around the world.
Ongoing studies
In a series of oral presentations, the group
discussed ongoing investigations of the RCN
and potential future collaborations over two
days of the meeting. The results are presented
in brief form below. The RCN research strategy
to date has been to perform large, multi-insti-
tutional retrospective reviews in disease types
who rarity prevents the acquisition of prospec-
tive data in clinical trials.Cardiac sarcoma (J. Thariat)
The prevalence of cardiac sarcomas in
autopsic series is less than 1%. Their median
survival is approximately 18 months. The treat-
ment consists of surgery when possible. The
role of chemotherapy and radiation therapy is
controversial, especially with respect to limit-
ing cardiac radiation dose that is theoretically
incompatible with the requirement of a tumo-
ricidal dose for sarcoma. A recent series of 124
cases of the French Sarcoma Group suggested
a benefit of radiation therapy on progression-
free survival. The SARCHEART project has two
aims: confirm the role of radiation therapy in
cardiac sarcomas and provide guidelines with
regard to dose, target volumes and technique.
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This ambispective study, using both a retro-
spective and prospective component, starts in
April 2014. All patients with cardiac sarcomas
treated between 2000 and 2014 are eligible.
Alerts will be sent to investigators for prospec-
tively included cases at 6, 12, 18 and 24 months
for follow up updates. Accrual will close in
March 2015.2Thyroid cancers (J. Thariat and X. S. Sun)Study 1 
Anaplastic/undifferentiated thyroid carcino-
mas have very poor prognosis, with median
survival of about 10 months. The overall man-
agement is debated in terms of surgical
aggressiveness, radiation modalities and role
for neoadjuvant and concomitant chemothera-
py (including taxanes and/or targeted thera-
pies). The primary aim of this RCN study was
to define the optimal surgery/chemo/radiation
therapy strategy. Other aims were to deter-
mine whether the presence of an associated
differentiated component was associated with
a better prognosis. Inclusion criteria are
patients receiving doses 40 Gy for ATC
between 2000 and 2011. One-hundred forty
patients have been included. At last follow-up,
18%, 19% and 29% had died with locoregional
failure, metastases or both. Median locore-
gional control, metastasis-free survival, and
survival were 16, 14 and 17 months. On multi-
variate analysis, surgery, chemo and higher
dose to high risk clinical target volumes for
locoregional control. On MVA, surgery and
high dose were prognostic factors for overall
survival. This study is being continued until
July 2014. 
Study 2
The second thyroid RCN study addresses a
very controversial issue: the benefit of irradia-
tion in select differentiated thyroid carcinomas.
External beam irradiation has been less and
less studied in the latest years, with failure to
recruit patients in prospective trials. A recent
EORTC protocol terminated early due to lack of
accrual. Based on ancient data, locally advanced
incompletely resected radioiodine negative thy-
roid cancers are thought potentially benefit
from external beam radiotherapy. We designed
a case control study for patients with high risk
(T3-4, N+, radioiodine negative) tumor. 147
patients have been included to date. The study
is being continued until September 2014. Adult medulloblastoma (B. Atalar)
Medulloblastoma is a common malignancy
in the pediatric patients with malignancies
affecting the central nervous system.
However, it accounts for only 1% of all adult
brain tumors and the data for adults is gener-
ally reported in very small series. Thus, there
is little consensus in the literature as to the
optimal treatment of adult patients.3 Due to
paucity of data because of the relative infre-
quency of adult medulloblastoma, treatments
are typically performed according to pediatric
protocols. We aimed to report the outcomes,
prognostic factors and the best treatment
strategy of a large group of adult patients by
the participation of our colleagues from RCN.
This project began in late 2011 and until now
we have collected the data of more than 100
patients from 8 centers. We believe we can
successfully accrue further patients with the
participation of other centers. 
Glomus tumors (Y. Lassen-Ramshad) 
Paraganglioma of the head and neck region
are rare, mostly benign, neuroendocrine
tumors.4 For this retrospective study, patient-,
tumor-, radiotherapy- and outcome data about
75 paraganglioma, treated with irradiation,
were submitted for analysis from 12 institu-
tions of the Rare Cancer Network. Survival,
local control and late toxicity data are being
analyzed. Preliminary analysis indicates that
the overall survival is good and that the treat-
ment is in general well tolerated, sometimes
late recurrences can occur. 
Proposed studies Primary hepatic lymphoma (G. Ugurluer) 
Primary hepatic lymphoma (PHL) is a rare
and difficult to diagnose lymphoproliferative
disorder. It constitutes less than 1% of all
extranodal non-Hodgkin’s lymphomas (NHL),
and only 0.01-0.02% of all cases of NHL. Most of
the cases present as a solitary lesion (50-60%).
There is little consistency in the literature
regarding treatment, and treatment options
include surgery, chemotherapy, radiation the-
rapy or varying combinations of these modali-
ties.5 The aim of study is to collect a significant
number of patients to provide some informa-
tion concerning the clinical outcome and the
best treatment strategy.Solitary fibrous tumors (J. Rooney) 
Solitary fibrous tumors in the brain are rare
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Figure 1. Geographic distribution of the Rare Cancer Network in
2014.
Figure 2. The First International Symposium of the Rare Cancer
Network, Nice, France, March 21-22, 2014.
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tumors with only 213 reported cases since it
was first described in the literature in 1996.6
Of these 213 cases, 166 involve the brain and
only 8 have been reported as malignant using
the criteria of high cellularity and more than 4
mitotic figures per 10 high power fields. Of
these 8 cases, only 3 cases have clinical
descriptions and outcomes. Due to this, a pro-
posal was made to gather other cases with the
goal of publishing a case series which would
describe clinical presentations, treatment, and
outcomes in order to help guide others when
counseling patient regarding the possible ben-
efits and risks of adjuvant treatment. Rosai-Dorfman disease (K. Chang) 
Sinus histiocytosis with massive lym-
phadenopathy, also known as Rosai-Dorfman
Disease (RDD), is a rare, idiopathic disease
marked by histiocyte proliferation primarily
affecting the lymph nodes, though extranodal
involvement is common. Diagnosis is histolog-
ically confirmed by the appearance of intact
lymphocytes within large histiocytes, known as
emperipolesis. While benign, localization in
vital organs is potentially fatal.7 To date, no
large studies have examined the outcomes in
RDD patients treated with radiotherapy. We
aim to retrospectively analyze the Rare Cancer
Network’s experience with patients in whom
RDD was managed with radiotherapy.Tumors of the ampulla of Vater (S. Krishnan) 
Ampullary cancers are rare tumors arising
from the ampulla of Vater that have a distinctly
better treatment outcome than pancreatic ade-
nocarcinomas and distal cholangiocarcinomas.
Whereas multiple large individual institutional
series have identified clinicopathologic prog-
nostic features of treatment outcome, they
have often lacked statistical power to draw firm
conclusions about the influence of tumor size,
nodal status, margin status, histologic grade,
and treatment choice on overall outcomes.
Combining large institutional series has
helped with improving statistical power and
validating some of the earlier findings of prog-
nostic markers in single-institution series.8,9
However, none of these studies has incorporat-
ed newer information about the molecular pro-
file of these tumors. Newer investigations
based on gene expression analyses have iden-
tified two distinct subsets of patients – those
with a pancreaticobiliary-like profile and con-
sequently a poorer prognosis and those with an
intestinal-like profile and a better prognosis.
Analysis of the influence of such a stratifica-
tion strategy on treatment outcomes for
ampullary cancer would be a relatively
straightforward exercise for a seasoned group
of investigators at the RCN and would move
the group towards more molecular/pathology-
based investigations than largely clinical
investigations. We therefore propose such a
study as one of the larger undertakings of the
group. Salivary gland tumors (X.S. Sunand J. Thariat) 
Malignant salivary gland tumors represent
less than 10% of all malignant tumors of the
head and neck. Tumor stage, poorly-differenti-
ated tumors, high grade transformation, extra-
capsular spread, perineural involvement, vas-
cular emboli, incomplete resection margins
are unfavorable prognostic factors. The main-
stay of treatment is surgery. According to the
NCCN, postoperative radiotherapy can be
advocated for undifferentiated and high-grade
tumors, advanced disease, cases with close or
positive margins, and/or in the presence of
perineural invasion, lymphatic/vascular inva-
sion, facial nerve involvement and/or deep lobe
involvement. With such poor prognostic fac-
tors, high dose radiation therapy is necessary
(65 Gy). Yet, local failure rates still approach
20% and distant metastases occur in about
20% with variable rates depending on histology
and grade. The choice of concurrent chemora-
diation has historically been extrapolated from
data in squamous cell carcinomas. Concurrent
chemotherapy (platinum given concurrently as
a radiosensitizer) may improve locoregional
control with high dose radiation therapy. The
aim of this study is to define the benefit of
adding chemotherapy to radiation therapy in
salivary gland cancers depending on factors
like histological subtypes.10Anorectal melanoma (C. Hallemeierand D. Azria) 
Mucosal melanoma of the anus or rectum is
a rare tumor with aggressive behavior. For
localized disease, the primary treatment is sur-
gical excision, although outcomes following
surgery remain poor. We propose a multi-insti-
tution study examining outcomes, prognostic
factors, and the role of adjuvant therapies for
this rare malignancy. Midline nuclear protein in testescarcinoma (R. Funk) 
Nuclear protein in testes (NUT) Midline
Carcinoma (NMC) presents as a rapidly pro-
gressive, poorly differentiated carcinoma of
the head and neck or midline thorax structures
with a predilection for younger patients and
with a median survival of 6.7 months. Since
NUT (nuclear protein in testes) expression in
normal tissue is limited to testes, detection of
NUT in carcinoma cells (with a commercially
available monoclonal antibody) is diagnostic.11
Because the biologic underpinnings defining
NMC were only recently discovered, little is
known about effective treatment strategies for
this rare and aggressive disease. We encour-
age Rare Cancer Network participants to con-
sider this diagnosis in patients with poorly dif-
ferentiated carcinomas of epithelial origin and
to collect details regarding presentation, diag-
nosis, therapy and outcomes for inclusion in
an RCN study.Pulmonary lymphoepithelioma-likecarcinoma (L.J. Zhang)
Pulmonary lymphoepithemlioma (LELC) is a
distinct group of non-small cell lung cancer
(NSCLC) that appears to affect younger, non-
smoking patients, and should be pathologically
confirmed by Immunohistochemistry and hema-
toxylin-eosin staining. The diagnosis of pul-
monary LELC should exclude the primary occur-
rence of nasopharyngeal carcinoma (NPC) due
to the similarity of morphology and EB virus-sus-
ceptibility.12 Genetic variations observed in
patients with NSCLC are rare in LELC patients.
Pulmonary LELC patients may receive a survival
benefit from multimodality treatment. Adenoid cystic carcinoma of thetrachea (P. van Houtte)
Primary tracheal cancers are uncommon dis-
ease representing 0.4% of all cancers and pri-
mary adenoid cystic carcinoma represents less
than 10%.13 Most series covered a long period
and included mainly surgical cases with or with-
out radiotherapy. Series of patients treated by
radiation alone are often case reports including
a few patients. The aim of this study is to have
more data on the role of radiation therapy espe-
cially through looking to patients treated during
the last two decades with modern technology
and staging procedure.Osteosarcomas of the mandible (J. Thariat) 
The literature suggests that head and neck
osteosarcomas behave differently from limb
osteosarcomas and that there is a role for radi-
ation therapy in incompletely resected facial
osteosarcomas. The RCN study on mandibular
osteosarcomas aimed to determine whether
head and neck osteosarcomas behaved similar-
ly as limb osteosarcomas and whether inter-
mediate grade behaved like high grade
osteosarcomas. The population was restricted
to the mandibular location because this loca-
tion usually allows wide resection margins
(with reconstructive surgery). It might thus
more easily help state on surgical practice and
the role of radiation therapy in patients with
completely resected tumors (including those
with no residual disease after neoadjuvant
chemotherapy). The study (n=111) suggested
to performed similar treatment in intermedi-
ate and high grades. It confirmed the role of
surgery and showed a benefit of chemotherapy
on survival rates, but failed to provide an
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answer for the role of radiotherapy (only one
5th of patients underwent radiation therapy).
The study is thus being continued to more
specifically address the role of radiation thera-
py. Additionally, Prof Brouchet-Gomes, bone
sarcoma pathologist in Toulouse, has accepted
to check the pathologic reports, and to review
blocks and perform molecular analyses.14Extra-cranial hemangiopericytoma(M. Krengli)
Hemangiopericytoma is a rare disease pre-
senting in most of the cases with intracranial
location. Data on extracranial hemangioperi-
cytoma come mainly from general reviews and
case reports.15 The purpose of the proposed
RCN study is to investigate clinical presenta-
tion, pathology features, treatment modalities,
and outcome in terms of local control and sur-
vival of extracranial hemangiopericytoma.
Special attention will be paid to the role of
radiotherapy in the treatment of this rare
tumor.Other studies
In addition to the studies listed above, the
RCN is currently has ongoing studies in the
subjects of male ductal carcinoma in situ of the
breast and lacrimal gland adenoid cystic carci-
noma. Further information can be found on the
RCN website at www.rarecancer.net. 
Issues in future research and conclusions 
The RCN has been dedicated in defining the
role of radiation therapy in rare tumors with
investigators from all over the world.
Institutional review board approval across
countries is critical and RCN radiation oncolo-
gists have been very strict in obtaining IRB for
their studies. Regulations are changing and
investigators are requested to ask for patient
consent if required to comply with their own
country regulations (that can be waived for
deceased patients in some nationalities). RCN
studies have been retrospective but there are
some suggestions that ambispective studies,
utilizing both retrospective and prospective
data acquisition, can be of help for diseases
with median survival of 2 years or less; provid-
ed that alerts can be sent to investigators for
follow up updates. Also, case control studies
including case patients that are irradiated and
control patients that are not may be useful to
limit selection biases and provide even higher
level of evidence for the role of radiation ther-
apy in rare diseases, adding to the major con-
tributions of the RCN to radiation therapy. The
role of irradiation will also be regarded with
respect to technological advances. 
The rapidly decreasing costs of genomic
characterization promises a new opportunity
for rare tumor research that may allow for
characterization of potential chemotherapeu-
tic targets for novel agents utilizing relatively
small sample sizes. Genomic profiling raises
the possibility of every tumor type becoming
rare through its unique genetic makeup.16
Additionally, advances in electronic medical
records and analytics may permit large popula-
tion based studies with more discrete end-
points than have been possible in the past with
resources such as the SEER database. The
RCN will need to evolve in structure and func-
tion to incorporate these new analytical tools
in order to retain its relevance in the 21st cen-
tury in area of increasing personalization of
medical science. 
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